Hept-6-enoic acid | CAS:1119-60-4

We serve Hept-6-enoic acid CAS:1119-60-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Hept-6-enoic acid

Chemical Name: Hept-6-enoic acid
CAS.NO:1119-60-4
Synonyms:
6-HEPTENOIC ACID
 
Molecular Formula:C7H12O2
Molecular Weight:128.16900
 
Physical and Chemical Properties:
Density:1.0±0.1 g/cm3
Boiling point:226ºC at 760mmHg
Melting point:-6.5ºC(lit.)
Flash point:113.3ºC
Index of Refraction:1.439
 
Specification:
Appearance:Light yellow or colorless transparent liquid
Purity:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a dry, inert atmosphere, keep container sealed and store in a cool, dry place
Application:Pharmaceutical intermediate



Contact us for information like Hept-6-enoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-HEPTENOIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-HEPTENOIC ACID Use and application,Hept-6-enoic acid technical grade,usp/ep/jp grade.


Related News: The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen’s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination.4-Fluorobenzaldehyde manufacturer The fine chemical industry includes fine chemicals and special chemicals. Fine chemical products have the characteristics of a small amount of production, relatively specific application fields, and long and complex industrial chains. They are mainly used in medicine, pesticides, dyes, liquid crystals and other fields.1-Benzo[b]thien-4-ylpiperazine monohydrochloride supplier The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.2,4-Dichlorobenzoyl chloride vendor The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”